Clinical and genetic risk factors for progressive fibrosis in metabolic dysfunction-associated steatotic liver disease.
Guadalupe Garcia-TsaoCraig C TeerlinkTae-Hwi Schwantes-AnTrina M Norden-KrichmarScott L DuvallTimothy R MorganPhilip S TsaoBenjamin F VoightJulie A LynchMarijana VujkovicKyong-Mi ChangPublished in: Hepatology communications (2024)
Linear trajectories of FIB4 correlated significantly with time to progression to cirrhosis, with liver-related outcomes among individuals with MASLD and with known and novel genetic loci. FIB4 slope may be useful as a surrogate measure of fibrosis progression.